stockrow
Friday 6 November 2026
Export KLRS’s income statement to Excel — free account
Kalaris Therapeutics Inc.
KLRS Healthcare Biotechnology
- EPS
- +21.3%
- Free cash flow
- +11.9%
Quarter to June 2026, against a year earlier
2.44
0.08
+3.39%
Follow KLRS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 1 | 0 | — | — | — | — | — | — | — | (85.5%) | — | — | — | — | |
| Gross margin, % | — | — | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (2) | (24) | (70) | (171) | (169) | (191) | (69) | (43) | (44) | +51.0% | ||||||
| EBT margin, % | — | — | (214.10) | (14,447.88) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +214.1 pt | ||||||
| Net income | — | 0 | (2) | (24) | (70) | (172) | (169) | (190) | (69) | (43) | (44) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.02 | 2.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.13) | (426.17) | (59.54) | (62.99) | (50.57) | (42.07) | (51.77) | (2.85) | (2.09) | +55.4% | ||||||
| Cash flow | — | — | 0.03 | (360.55) | (51.98) | (38.93) | (42.60) | (27.51) | (15.47) | (2.51) | (1.72) | n/m | ||||||
| Capex | — | — | 0.00 | (6.06) | (0.20) | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | — | — | 0.03 | (366.62) | (52.18) | (38.94) | (42.60) | (27.51) | (15.47) | (2.53) | (1.72) | n/m | ||||||
| Book value | — | — | 0.33 | (921.34) | 301.76 | 82.48 | 67.33 | 32.22 | (72.32) | 5.16 | 2.42 | +48.0% | ||||||
| Shares, m | — | — | 65 | 0 | 1 | 3 | 3 | 5 | 1 | 15 | 20 | (18.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | ||||||
| P/B | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 1.01 | 0.0 | ||||||
| EV/Sales | — | — | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | 0.83 | 0.83 | — | — | — | — | — | — | 0.39 | 0.8 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | 2 | (20) | (61) | (106) | (142) | (124) | (21) | (38) | (41) | n/m | |||||
| Capex | — | — | — | 0 | 0 | 0 | — | — | — | 0 | 0 | (8.4%) | ||||||
| Free cash flow | — | — | 2 | (20) | (61) | (106) | (142) | (124) | (21) | (39) | (41) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 22 | 118 | 349 | 215 | 219 | 159 | (22) | 109 | 87 | +26.1% | |||||
| Net debt | — | — | (25) | (123) | (353) | (242) | (227) | (184) | 18 | (118) | (94) | +24.8% | ||||||
| Shareholders’ equity | — | — | 22 | (52) | 353 | 225 | 225 | 146 | (97) | 79 | 58 | +20.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (64.43) | (28.94) | (27.35) | (52.31) | (59.86) | (81.40) | (70.24) | (67.93) | (46.02) | (3.5) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 19.86 | 58.06 | (46.28) | (59.47) | (75.02) | (102.85) | (281.37) | 488.01 | (79.91) | +468.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 21 | 53 | 107 | 106 | 112 | 6 | 20 | — | (0.8%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2019 · fundamentals updated 25 Oct 2026
Kalaris Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics, Inc. | $53.2M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $53.1M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| RNTX Rein Therapeutics Inc. | $52.8M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $52.3M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $51.7M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $51.6M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | |
| INKT MiNK Therapeutics, Inc. | $51.3M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OSTX OS Therapies Incorporated | $51.3M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| PLRX Pliant Therapeutics, Inc. | $50.5M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $52.0M | — | — | −53.85% | — | −29.60% | 34.64% | 0.00% |